Preotact®

Product description: Preotact® (parathyroid hormone), in-licensed from NPS, is prescribed for the treatment of osteoporosis in post-menopausal women with a high risk of fractures.

The Preotact® Pen is especially designed to simplify the injection process for osteoporosis patients, which encourages compliance to treatment. Over 30,000 patients have already benefited from Preotact®, making it one of Nycomed’s top ten products.

Preotact® is in-licensed from NPS Pharmaceuticals.

Medical need: Osteoporosis causes bones to become brittle and leads to increased fractures. This disease places a significant burden on both the individual sufferer and society as a whole. The World Health Organisation (WHO) has ranked osteoporosis as one of the top ten global disease of the 21st century.

Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.